Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08634404 vs Pembrolizumab in pMMR Endometrial Cancer
NCT07578649Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Oct 2026
- Primary completion
- Jun 2029
- Modality
- Bispecific Antibodies
- Countries
- 5
01
Overview
A Phase 3 trial of PF-08634404 in endometrial cancer (EC), sponsored by Pfizer. Started Oct 2026; status: recruiting.
02
Drugs
PF-08634404
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT07578649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07578649.